SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFY.L Regulatory News (FFY)

  • There is currently no data for FFY

Form 8.3 - Fyffes Plc (replacement)

1 Feb 2017 16:34

RNS Number : 7914V
Societe Generale SA
01 February 2017
 

Ap19

 

AMENDED FORM

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1. KEY INFORMATION

 

Name of person dealing (Note 1)

Société Générale S.A.

Company dealt in

Fyffes pIc

Class of relevant security to which the dealings being disclosed relate (Note 2)

€0.06 ordinary shares

Date of dealing

26/01/2017

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

16,055,046

4.87

0

0.00

(2) Derivatives (other than options)

0

0.00

8,411,781

2.55

(3) Options and agreements to purchase/sell

0

0.00

0

0.00

Total

16,055,046

4.87

8,411,781

2.55

 

 

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Ap20

 

 

1. DEALINGS (Note 4)

 

(a) Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit EUR (Note 5)

Purchase

20,000

2.2393

Purchase

420,000

2.24012

Sale

-

-

Total Purchases

440,000

Total Sales

-

 

*Assignment of shares for collateral purpose (7,570,749 shares) included in the total holding.

 

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit EUR (Note 5)

CFD

Increased Short

20,000

2.2393

CFD

Increased Short

420,000

2.24012

 

 

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

Ap21

 

2. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. If none, 

this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)  NO

 

Date of disclosure

01/02/2017

Contact name

Disclosure team

Telephone number

+33 1 42 14 92 74

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISELLFVRFIILIID
Date   Source Headline
29th Jul 20119:28 amRNSHolding(s) in Company
6th Jul 201111:47 amRNSHolding(s) in Company
1st Jul 201112:54 pmRNSBlocklisting Interim Review
12th May 20112:10 pmRNSAGM Statement
12th May 20117:00 amRNSTrading Statement
15th Apr 201112:31 pmRNSAnnual Financial Report
5th Apr 201111:00 amRNSHolding(s) in Company
18th Mar 20114:10 pmRNSAcquisition
16th Mar 20115:15 pmRNSHolding(s) in Company
15th Mar 20114:25 pmRNSDirectorate Change
2nd Mar 20117:00 amRNSPreliminary Results Y/E 31 December 2010
22nd Feb 201112:32 pmRNSNotice of Results
2nd Feb 20113:46 pmRNSHolding(s) in Company
26th Jan 20115:46 pmRNSAcquisition
11th Jan 20113:20 pmRNSTrading Statement
4th Jan 20113:38 pmRNSBlocklisting Interim Review
31st Dec 201010:13 amRNSDirector/PDMR Shareholding
20th Dec 20103:35 pmRNSDirector/PDMR Shareholding
6th Dec 20102:55 pmRNSHolding(s) in Company
25th Nov 20103:03 pmRNSHolding(s) in Company
22nd Nov 20104:59 pmRNSHolding(s) in Company
22nd Nov 20103:06 pmRNSHolding(s) in Company
19th Nov 201011:15 amRNSHolding(s) in Company
18th Nov 20104:53 pmRNSHolding(s) in Company
18th Nov 20103:39 pmRNSHolding(s) in Company
18th Nov 201010:08 amRNSTransaction in Own Shares
17th Nov 20104:28 pmRNSPurchase Of Own Shares
17th Nov 20102:52 pmRNSHolding(s) in Company
8th Nov 20104:36 pmRNSHolding(s) in Company
3rd Sep 20107:00 amRNSFyffes plc - Interim Results to 30 June 2010
31st Aug 20107:00 amRNSNotice of Interim Results
24th Jun 20103:49 pmRNSHolding(s) in Company
18th Jun 20104:40 pmRNSSecond Price Monitoring Extn
18th Jun 20104:35 pmRNSPrice Monitoring Extension
13th May 20103:38 pmRNSResult of AGM
5th May 20103:43 pmRNSBlocklisting Interim Review
26th Apr 20105:03 pmRNSTrading Statement
13th Apr 20109:31 amRNSAnnual Financial Report
5th Mar 20107:00 amRNSFinal Results
26th Feb 20102:52 pmRNSHolding(s) in Company
26th Feb 201011:55 amRNSNotice of Results
13th Jan 20105:19 pmRNSHolding(s) in Company
11th Jan 201011:54 amRNSTrading Statement
17th Dec 20094:37 pmRNSDirector/PDMR Shareholding
27th Nov 200911:40 amRNSHolding(s) in Company
25th Nov 20092:41 pmRNSHolding(s) in Company
13th Nov 20099:41 amRNSHolding(s) in Company
23rd Oct 20094:01 pmRNSHolding(s) in Company
7th Oct 20093:39 pmRNSBlocklisting Interim Review
29th Sep 200911:13 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.